MUFG Securities EMEA plc boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 74.0% in the third quarter, Holdings Channel reports. The institutional investor owned 435,000 shares of the company’s stock after acquiring an additional 185,000 shares during the period. Johnson & Johnson comprises approximately 2.0% of MUFG Securities EMEA plc’s investment portfolio, making the stock its 6th biggest holding. MUFG Securities EMEA plc’s holdings in Johnson & Johnson were worth $56,554,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after acquiring an additional 3,023,110 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after acquiring an additional 4,332,612 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Johnson & Johnson by 0.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock worth $4,757,593,000 after acquiring an additional 130,437 shares during the last quarter. FMR LLC lifted its stake in shares of Johnson & Johnson by 5.9% during the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after acquiring an additional 1,509,745 shares during the last quarter. Finally, Capital World Investors lifted its stake in shares of Johnson & Johnson by 4.1% during the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock worth $3,507,009,000 after acquiring an additional 1,050,000 shares during the last quarter. 65.58% of the stock is owned by institutional investors.
Shares of Johnson & Johnson (JNJ) opened at $132.07 on Tuesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. The firm has a market capitalization of $354,810.00, a price-to-earnings ratio of 24.32, a PEG ratio of 2.21 and a beta of 0.74. Johnson & Johnson has a 52-week low of $120.95 and a 52-week high of $148.32.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.54%. Johnson & Johnson’s payout ratio is 61.88%.
JNJ has been the subject of a number of research analyst reports. BTIG Research reissued a “sell” rating and set a $110.00 price target on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Vetr lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $147.40 price target for the company. in a research note on Monday, January 8th. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the stock a “hold” rating in a report on Monday, January 22nd. BMO Capital Markets raised their price objective on Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a report on Tuesday, December 12th. Finally, Wells Fargo & Co restated an “outperform” rating and set a $160.00 price objective (up from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $146.16.
In other news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the sale, the vice president now owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.19% of the stock is owned by company insiders.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.